INTRODUCTION
Hepatitis B virus (HBV) remains a major global health challenge, with chronic HBV infection (CHB) manifesting in varied clinical phases. To better understand the molecular underpinnings of CHB, this study aimed to characterize HBV DNA integration profiles across distinct stages of infection. Liver biopsies from 55 patients, categorized by their CHB phase, were analyzed using high-throughput next-generation sequencing (NovaSeq-6000) with target-capture technology. The profiles were then interpreted via the AVID platform, focusing on integration events marked by chimeric fusions supported by soft-clipped and total reads. This comprehensive approach sought to illuminate patterns and frequency of viral genome integration in liver tissue, contributing valuable insights into HBV's persistence and progression.
PATIENT STRATIFICATION AND SAMPLING
To capture a holistic view of HBV integration, patients were stratified into six clinical categories based on HBsAg and HBeAg serostatus, as well as ALT levels. This stratification included active infection, chronic hepatitis, resolved infection with seroclearance, and occult HBV infection. This broad sampling strategy allowed researchers to investigate integration patterns throughout the natural course of HBV infection, facilitating comparisons across different disease states. Such diverse sampling enhances the validity of the findings and enables the identification of patterns that may inform personalized therapeutic strategies.
INTEGRATION FREQUENCY ACROSS CHB PHASES
HBV integration was ubiquitous among HBsAg-positive patients and still significantly present in patients with HBsAg-seroclearance and occult HBV, albeit at reduced frequencies. A clear stepwise decrease in the number of HBV integration events was observed as patients transitioned from active infection to inactive or resolved states. This suggests a potential link between viral integration and antigen expression, reinforcing the importance of integration profiling in understanding HBV persistence mechanisms. Notably, integration frequency was not influenced by ALT levels, indicating that inflammation severity does not correlate directly with HBV DNA integration load.
MOLECULAR CHARACTERIZATION OF BREAKPOINTS
Detailed analysis revealed that HBV DNA consistently integrated around nucleotide 1800 of the viral genome, regardless of disease phase. This recurring breakpoint suggests a preferential site for viral integration, possibly tied to the structural or functional attributes of the HBV genome. On the human side, integration frequently involved the LINC00486 gene, a non-coding RNA with yet-to-be-clarified roles in liver pathology. These breakpoint patterns may have implications for oncogenesis or long-term viral latency and could serve as biomarkers or therapeutic targets in future research.
TECHNOLOGICAL ADVANCEMENTS IN INTEGRATION DETECTION
The study leveraged state-of-the-art target-capture next-generation sequencing using the NovaSeq-6000 platform, enhancing sensitivity and specificity in detecting HBV integration events. The AVID platform's ability to detect integrations based on soft-clipped reads and total read depth adds a layer of robustness to the methodology. This technological approach allows precise mapping of integration sites and facilitates comparisons across different patient groups. These tools represent the cutting edge of viral genome integration research and are instrumental in defining the molecular footprint of chronic viral infections like HBV.
IMPLICATIONS FOR NATURAL HISTORY AND THERAPEUTIC TARGETING
The study’s findings significantly enhance our understanding of HBV’s natural history by linking viral integration profiles to clinical disease phases. By establishing that integration persists even after seroclearance and in occult infections, the research underscores the challenge of achieving true viral eradication. These insights may influence the development of antiviral therapies aimed at not just suppressing replication but also eliminating integrated viral DNA. Furthermore, the frequent involvement of specific genomic loci like LINC00486 may pave the way for targeted interventions and risk stratification for liver disease progression or hepatocellular carcinoma.
👉 Visit: https://infectious-diseases-conferences.pencis.com
🏆 Nominate Now: https://infectious-diseases-conferences.pencis.com/award-nomination/?ecategory=Awards&rcategory=Awardee
📝 Register: https://infectious-diseases-conferences.pencis.com/award-registration/
📧 Contact: infectioussupport@pencis.com
Hashtags
#HBVIntegration, #ChronicHepatitisB, #HBVResearch, #LiverBiopsy, #HBVDNA, #OccultHBV, #HBeAg, #HBsAg, #Seroclearance, #NextGenerationSequencing, #NovaSeq6000, #ViralIntegration, #LINC00486, #HepatitisB, #HBVGenome, #TargetCapture, #CHBProgression, #LiverDiseaseResearch, #MolecularVirology, #HepatologyResearch,
No comments:
Post a Comment